Project Grant R03AI190704
Award Date 8/8/25
Completion Date 7/31/27
Dollars Obligated $161K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will support the development of a panel of antibodies to detect markers of Trypanosoma cruzi infection, the causative agent of Chagas disease. The $449,408 award to Duke University, with a performance period from Jul 1, 2025 to Jun 30, 2027, aims to generate antibodies that can effectively diagnose acute and chronic Chagas...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $133,746 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Fundacion Instituto De Investigaciones Biotecnologicas, a non-profit research institute in Buenos Aires, Argentina. The grant supports high-throughput analysis of antibody responses against defined epitopes to prioritize diagnostic and prognostic markers for Chagas disease, a parasitic infection endemic to the Americas. The...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $504,703 to the University of Georgia Research Foundation (UGA Research Foundation) to optimize a PCR-based assay for detecting and quantifying Trypanosoma cruzi infection. The key objectives are to increase the sensitivity of PCR detection of T. cruzi DNA in blood samples through techniques such as DNA fragmentation...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $123,280 project grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Instituto De Biologia Molecular Y Celular De Rosario (IBR) in Argentina. The grant aims to investigate the adaptive immune response against Trypanosoma cruzi, the parasite that causes Chagas disease, with the goal of developing effective vaccine candidates. The research will focus on enhancing CD8+ T cell...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $133,800 to the Fundacion Instituto De Investigaciones Biotecnologicas in Argentina. The funding supports research to fully understand protein trafficking through the contractile vacuole complex (CVC) in the parasite Trypanosoma cruzi, the causative agent of Chagas disease. The research aims to...
- The University of Cincinnati was awarded a $444,688 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will fund research to characterize cyclic AMP (cAMP) signaling microdomains in the human pathogen Trypanosoma cruzi, which causes Chagas disease - a leading cause of disability and premature death in the Americas. Specifically, the research aims to study the role of cAMP in the...
- The University of Texas Medical Branch at Galveston (UTMB) received a $440,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), to examine the role of the long non-coding RNA (lncRNA) CHAST in regulating the host immune response to Trypanosoma cruzi (T. cruzi) infection, the causative agent of Chagas disease. The project aims to elucidate how T. cruzi deregulates CHAST...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $155,686 Project Grant to Baylor College of Medicine under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to optimize Strongyloides testing in an at-risk U.S. population. This project aims to address the public health challenge of strongyloidiasis, a parasitic infection that can cause severe disease in immunosuppressed individuals. The research will focus on improving diagnostic...
- This $412,581 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to define the roles of specialized mitochondrial DNA polymerases (POLIB and POLID) in the replication and maintenance of the complex kinetoplast DNA network of African trypanosomes. These parasites cause neglected tropical diseases such as human African trypanosomiasis, Chagas disease,...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop and validate nanotherapies to address three key issues in the treatment of chronic Chagas disease. The $666,319 award to the University of Virginia supports research to: 1) Treat chronic Chagas cardiomyopathy without impacting parasitemia or parasite reservoirs, 2) Eliminate parasite reservoirs in adipose tissue, and 3) Improve drug delivery and efficacy of...